Advertisement

Defining and classifying terminology for medication harm: a call for consensus

  • Nazanin Falconer
  • Michael Barras
  • Jennifer Martin
  • Neil Cottrell
Review
  • 42 Downloads

Abstract

Purpose

The multiplicity in terms and definitions of medication-related harm has been a long-standing challenge for health researchers, clinicians, and regulatory bodies. The purpose of this narrative review was to report the diversity of terms; compare definitions, classifications, and models describing medication harm; and suggest which may be useful in both clinical practice and the research setting.

Methods

A narrative review of key studies defining and/or classifying medication harm terminology was undertaken.

Results

This review found that numerous terms are used to describe medication harm, and that there is a lack of consistency in current definitions, classifications, and applications. This lack of consistency applied across clinical jurisdictions and regulatory terminologies. A number of limitations in current definitions and classifications were identified. These included the exclusion of key types of medication harm events, ambiguous wording, and a lack of clarity and consensus on subclassifications. In general, there was some overlap in key models from the literature and these were presented to describe similarities and differences.

Conclusion

Without uniformity quantifying, comparing, combining, or extrapolating medication harm data, such as a rate of harm in a specific population, is a challenge for those involved in medication safety and pharmacovigilance. There is a pressing need for further discussion and international consensus on this topic. Adoption of standard descriptors by practitioner groups, regulatory and policy organisations would foster quality improvement and patient safety.

Keywords

Adverse drug events Adverse drug reactions Medication errors Medication harm Drug-related problems 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Supplementary material

228_2018_2567_MOESM1_ESM.docx (14 kb)
ESM 1 (DOCX 14 kb)

References

  1. 1.
    Agency for Healthcare Research and Quality. Medication Errors 2017. Available from: https://psnet.ahrq.gov/primers/primer/23/medication-errors
  2. 2.
    Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M (2009) Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 4(2):e4439CrossRefGoogle Scholar
  3. 3.
    Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200–1205CrossRefGoogle Scholar
  4. 4.
    Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ 329(3)CrossRefGoogle Scholar
  5. 5.
    Budnitz DS, Lovegrove MC, Shehab N, Richards CL (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365(21):2002–2012CrossRefGoogle Scholar
  6. 6.
    Trivalle C, Burlaud A, Ducimetière P (2011) Risk factors for adverse drug events in hospitalized elderly patients: a geriatric score. European Geriatric Medicine 2(5):284–289CrossRefGoogle Scholar
  7. 7.
    Falconer N, Barras MA, Cottrell WN (2018) Systematic review of predictive risk models for adverse drug events in hospitalised patients. Br J Clin Pharmacol 84(5):846–864CrossRefGoogle Scholar
  8. 8.
    World Health Organisation. Glossary of Patient Safety Concepts and References 2009Google Scholar
  9. 9.
    Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis and management. Lancet 356(9237):1255–1259CrossRefGoogle Scholar
  10. 10.
    Ackroyd-Stolarz S, Hartnell N, McKinnon NJ (2006) Demystifying medication safety: making sense of the terminology. Res Soc Adm Pharm 2:280–289CrossRefGoogle Scholar
  11. 11.
    Yu KH, Nation RL, Dooley MJ (2005) Multiplicity of medication safety terms, definitions and functional meanings: when is enough enough? Qual Saf Health Care 14:358–363CrossRefGoogle Scholar
  12. 12.
    Lisby M, Nielsen LP, Brock B, Mainz J (2010) How are medication errors defined? A systematic literature review of definitions and characteristics. Int J Qual Health Care 22:507–518CrossRefGoogle Scholar
  13. 13.
    Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD (1990) Drug-related problems: their structure and function. Drug Intell Clin Pharm 24:1093–1097Google Scholar
  14. 14.
    Bates DW, Boyle DL, Vander Vliet MB, Schneider J, Leape L (1995b) Relationship between medication errors and adverse drug events. J Gen Intern Med 10:199–205CrossRefGoogle Scholar
  15. 15.
    American Society of Health-System Pharmacists (1998) Suggested definitions and relationships among medication misadventures, medication errors, adverse drug events and adverse drug reactions. Am J Health Syst Pharm 55:165–166Google Scholar
  16. 16.
    Rawlins M, Thompson JW (1977) Pathogenesis of adverse drug reactions: textbook of adverse drug reactions. Oxford University Press, OxfordGoogle Scholar
  17. 17.
    Meyboom RH, Lindquist M, Egberts AC (2000) An ABC of drug-related problems. Drug Saf 22(6):415–423CrossRefGoogle Scholar
  18. 18.
    Nebeker JR, Barach P, Samore MH (2004) Clarifying adverse drug events: a clinician’s guide to terminology, documentation and reporting. Ann Intern Med 140:795–801CrossRefGoogle Scholar
  19. 19.
    Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW (2004) Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care. 13(4):306–314CrossRefGoogle Scholar
  20. 20.
    National Coordinating Centre for Medication Error Reporting and Prevention (NCC MERP). Taxonomy for Medication Errors 2005 [cited 2018 5 Jan]. Available from: http://www.nccmerp.org/taxonomy-medication-errors-now-available
  21. 21.
    Otero López MJ, Dominguez-Gil A (2000) Adverse drug events: an emerging pathology. Pharm Hosp 24(4):258–266Google Scholar
  22. 22.
    Otero MJ, Schmitt E (2005) Comments and responses: Clarifying terminology for adverse drug events. Ann Intern Med 142:77CrossRefGoogle Scholar
  23. 23.
    Aronson JK, Ferner RE (2005) Classification of terminology in drug safety. Drug Saf 28(10):851–870CrossRefGoogle Scholar
  24. 24.
    The PCNE Classification V 7.0 [Internet]. Pharmaceutical Care Network Europe Foundation. 2016 [cited 19th March 2017]. Available from: http://www.pcne.org/working-groups/2/drug-related-problems
  25. 25.
    Bürkle T, Müller F, Patapovas A, Sonst A, Pfistermeister B, Plank-Kiegele B, Dormann H, Maas R (2013) A new approach to identify, classify and count drug-related events. Br J Clin Pharmacol 76:56–58CrossRefGoogle Scholar
  26. 26.
    Canadian Patient Safety Institute. The Economics of Patient Safety in Acute Care - Technical Report 2018. Available from: http://www.patientsafetyinstitute.ca/en/search/pages/results.aspx?k=adverse%20drug%20events
  27. 27.
    European Medicines Agency. Question and answer document on the European database of adverse drug reaction reports website London2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/05/WC500127958.pdf
  28. 28.
    International Conference on Harmonisation (ICH). Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting 2003. Available from: http://www.ich.org/home.html
  29. 29.
    Institute For Healthcare Improvement (IHI). Adverse Drug Events per 1000 2018. Available from: http://www.ihi.org/resources/Pages/Measures/ADEsper1000Doses.aspx
  30. 30.
    Institute for Safe Medication Practices. ISMP Medication Safety Alert! Adverse drug reactions: documentation is important but communication is critical Horsham, PA.2018. Available from: http://www.ismp.org/Newsletters/acutecare/articles/20000906.asp
  31. 31.
    Therapeutic Goods Administration. Reporting adverse drug reactions 2014. Available from: https://www.tga.gov.au/publication/reporting-adverse-drug-reactions#whattoreport
  32. 32.
    Aronson JK (2009) Medication errors: definitions and classification. Br J Clin Pharmacol 67(6):599–603CrossRefGoogle Scholar
  33. 33.
    The use of the WHO-UMC system for standardised case causality assessment [Internet]. Uppsala Monitoring Centre. [cited 2 Jan 2018]. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf
  34. 34.
    Naranjo CA, Busto U, SE M, Sandor P, Ruiz I (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245CrossRefGoogle Scholar
  35. 35.
    Hallas J, Harvald B, Gram LF, GRODUM E, BROSEN K, HAGHFELT T et al (1990) Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 228(2):83–90CrossRefGoogle Scholar
  36. 36.
    Bates DW, Cullen DJ, Laird N, Peterson LA, Small SD, Servi D et al (1995a) Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 274:29–34CrossRefGoogle Scholar
  37. 37.
    Aronson JK, Ferner RE (2003) Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 327(7425):1222–1225CrossRefGoogle Scholar
  38. 38.
    Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, Hebert L, Newhouse JP, Weiler PC, Hiatt H (1991) The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 324(6):377–384CrossRefGoogle Scholar
  39. 39.
    Kohn LT, Corrigan JM, Donaldson MS (1999) To err is human - building a safer health system. National Academy Press, Washington, DCGoogle Scholar
  40. 40.
    International Conference on Harmonisation (ICH). Medical Dictionary for Regulatory Activities MedDRA - version 20.0 2017. Available from: https://www.meddra.org/how-to-use/support-documentation?current
  41. 41.
    Aronson JK, Ferner RE (2010) Preventability of drug-related harms — part II. Drug Saf 33(11):995–1002CrossRefGoogle Scholar
  42. 42.
    Hepler CD, Strand LM (1990) Oppurtunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 47:533–543Google Scholar
  43. 43.
    Mirbaha F, Shalviri G, Yazdizadeh B, Gholami K, Majdzadeh R (2015) Perceived barriers to reporting adverse drug events in hospitals: a qualitative study using theoretical domains framework approach. Implement Sci 10:110CrossRefGoogle Scholar
  44. 44.
    Evans SM, Berry JG, Smith BJ, Esterman A, Selim P, O’Shaughnessy J, DeWit M (2006) Attitudes and barriers to incident reporting: a collaborative hospital study. Qual Saf Health Care 15(1):39–43CrossRefGoogle Scholar
  45. 45.
    Walter SR, Day RO, Gallego B, Westbrook JI (2017) The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia. Br J Clin Pharmacol 83:416–426CrossRefGoogle Scholar
  46. 46.
    Hohl C, Karpov A, Reddekopp L, Stausberg J (2014) ICD-10 codes used to identify adverse drug events in administrative data: a systematic review. J Am Med Inform Assoc 21:547–557CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.School of Pharmacy, Pharmacy Australia Centre of ExcellenceThe University of QueenslandBrisbaneAustralia
  2. 2.Princess Alexandra HospitalMetro South HealthBrisbaneAustralia
  3. 3.School of Medicine and Public HealthThe University of New CastleCallaghanAustralia
  4. 4.The Hunter Medical Research InstituteNew LambtonAustralia

Personalised recommendations